Search

A retrospective study involving 14 patients was conducted to investigate the efficacy of dalbavancin in treating prosthetic valve endocarditis, prosthetic vascular graft infection, and cardiac implantable electronic devices infection caused by methicillin-sensitive Staphylococcus aureus. The patients, aged between 50 and 80 years, had previously received other treatments such as doxycycline, rifampicin, daptomycin, ceftriaxone, cefazolin, or teicoplanin. Despite receiving dalbavancin therapy, there was no clinical success, and unfortunately, two patients died as a result of their infections. This suggests that dalbavancin may not be effective in treating these specific infections. [Extracted from the article]

A 70-year-old woman with a history of osteoporosis and bilateral knee replacement exhibited lack of efficacy during treatment with vancomycin and daptomycin for methicillin-resistant S aureus (MRSA) bacteraemia. Despite receiving vancomycin, she continued to have fevers and cultures showed MRSA growth, indicating lack of efficacy. Her treatment was switched to daptomycin, but she still grew MRSA in all cultures, indicating lack of efficacy again. Additionally, she developed cholecystitis secondary to MRSA bacteraemia. [Extracted from the article]

In a retrospective study involving 50 patients with vascular graft and endograft infections, a case was reported of a patient who developed eosinophilic pneumonia while being treated with daptomycin. The patient's age, sex, and specific treatment details were not provided. Eosinophilic pneumonia is a rare but serious side effect of daptomycin. This case highlights the need for careful monitoring and consideration of alternative treatments in patients receiving daptomycin for vascular graft and endograft infections. [Extracted from the article]

An 86-year-old woman developed eosinophilic pneumonia while receiving antibiotic therapy with daptomycin for cellulitis in her right lower extremity. She had a history of hypertension, diabetes mellitus, and cellulitis in her left lower extremity, which had resulted in a below knee amputation. After two weeks of daptomycin therapy, she experienced worsening respiratory failure and was found to have bilateral pulmonary opacifications consistent with pneumonia. She was transferred to the ICU, where her antibiotic therapy was changed and she was treated with hydrocortisone. She eventually made a full recovery and was transferred to a general medical floor. [Extracted from the article]

A 76-year-old man developed acute eosinophilic pneumonia (AEP) and eosinophilic pleural effusion (EPE) while being treated with daptomycin for a penile implant infection. Despite receiving broad-spectrum antibiotics, his condition worsened with symptoms including leukocytosis, fevers, and hypoxemia. Diagnostic tests confirmed the presence of eosinophils in his bronchoalveolar lavage and pleural effusion, and other infectious causes were ruled out. Treatment with methylprednisolone and prednisone resulted in near complete resolution of the symptoms. [Extracted from the article]

A 63-year-old man with end-stage renal disease developed acquired drug resistance to dalbavancin, daptomycin, and vancomycin after being treated for methicillin-resistant Staphylococcus aureus (MRSA). He initially received ceftriaxone and azithromycin, but was later diagnosed with MRSA and treated with vancomycin. Imaging tests revealed septic emboli and an infected pseudoaneurysm, leading to surgical resection. Despite subsequent treatment with dalbavancin and daptomycin, the patient developed infective endocarditis and the resistance was associated with specific mutations. Ceftaroline-fosamil and linezolid were used as alternative therapies, and the patient underwent multiple valve replacements. No further positive cultures were detected during one year of follow-up. [Extracted from the article]

A 46-year-old man developed eosinophilic pneumonia while being treated with daptomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. The patient had a medical history of end stage renal disease and presented with shortness of breath and a syncopal episode. Diagnostic tests confirmed the diagnosis of daptomycin-induced eosinophilic pneumonia. The patient was immediately taken off daptomycin and started on other medications, including corticosteroids, which resulted in a significant improvement in symptoms. [Extracted from the article]

A 46-year-old man developed eosinophilic pneumonia while being treated with daptomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. The patient had a medical history of end stage renal disease and presented with shortness of breath and a syncopal episode. Diagnostic tests confirmed the diagnosis of daptomycin-induced eosinophilic pneumonia. The patient was immediately taken off daptomycin and started on other medications, including corticosteroids, which resulted in a significant improvement in symptoms. [Extracted from the article]

A male neonate developed hypereosinophilia during off-label treatment with daptomycin for Methicillin-resistant Staphylococcus epidermidis (MRSE) and Staphylococcus capitis endocarditis. He exhibited lack of efficacy during treatment with meropenem and vancomycin for MRSE infection and Staphylococcus capitis endocarditis. The boy experienced complications including fetal bradycardia, respiratory distress syndrome, and septic appearance. After discontinuing vancomycin and meropenem, he was treated with off-label daptomycin, which led to significant improvement but also caused hypereosinophilia. The neonate eventually recovered and showed normal development and growth. [Extracted from the article]

A 90-year-old woman developed acute interstitial pneumonia while being treated with daptomycin for osteomyelitis. She presented to the emergency department with progressive dyspnea and her symptoms had been worsening for a week. Chest x-ray and CT scan showed bilateral opacities and significant mediastinal lymphadenopathy. The woman's daptomycin therapy was discontinued and she was treated with prednisone. [Extracted from the article]

A 75-year-old man developed acute eosinophilic pneumonia while being treated with daptomycin for osteomyelitis and discitis. He presented at the emergency department with symptoms of fever, dyspnea, cough, and hypoxia. Laboratory investigations revealed an elevated eosinophil count, and a CT scan showed lung abnormalities consistent with eosinophilic pneumonia. The man's treatment with daptomycin was discontinued, and he was started on prednisone. After a six-month period of treatment and follow-up, his symptoms and radiological abnormalities resolved. [Extracted from the article]

A 66-year-old man developed acute eosinophilic pneumonia while being treated with daptomycin for a streptococcal infection. He had been discharged from the hospital five weeks prior after being treated for the same infection. The man experienced symptoms such as dyspnea, fever, and cough, and sought medical attention multiple times. His condition was confirmed through bronchoalveolar lavage, and he was switched to a different antibiotic and started on prednisone. His symptoms improved rapidly after the change in treatment. [Extracted from the article]

A 54-year-old man developed acute eosinophilic pneumonia while being treated with daptomycin for osteomyelitis. Within two weeks of starting the treatment, he experienced respiratory failure and was transferred to the ICU. He had symptoms such as fever, difficulty breathing, and a non-productive cough. Tests showed peripheral eosinophilia and bilateral infiltrates in his lungs. The man's condition worsened despite receiving other antibiotics, but improved after daptomycin was stopped and he started receiving methylprednisolone. The acute eosinophilic pneumonia was believed to be caused by daptomycin. [Extracted from the article]

A retrospective study described three patients, aged 75-88 years, who developed acute eosinophilic pneumonia (AEP) while being treated with daptomycin, amiodarone, or minocycline. The first patient, a 75-year-old woman, developed AEP while receiving minocycline and was successfully treated with antibiotics and steroids. The second patient, an 88-year-old man, developed AEP while receiving daptomycin and was also treated with antibiotics, leading to improvement. The third patient, an 81-year-old woman, developed AEP while receiving amiodarone and was treated with steroids, resulting in improvement. All three patients survived and were discharged. [Extracted from the article]

A multicenter retrospective cohort study examined the treatment outcomes of 8 patients with prosthetic joint or vascular infections between 2016 and 2018. The study found that 6 patients experienced treatment failure with daptomycin and linezolid, and two of these patients also developed asthenia, liver injury, or kidney injury while receiving dalbavancin as suppressive antibiotic therapy. The patients had various infections caused by Enterococcus faecium, Staphylococcus epidermidis, Staphylococcus intermedius, or Streptococcus gallolyticus. Some patients received alternative antibiotics, but treatment failure persisted in some cases. One patient died after starting dalbavancin, and two patients experienced adverse events related to dalbavancin. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 69-year-old woman developed hyperkalaemia during treatment with daptomycin as antibiotic therapy. Additionally, she developed multiple bowel movements during treatment with cefepime, vancomycin and piperacillin/tazobactam as antibiotic therapy [not all dosages, routes and outcomes stated, duration of treatment to reaction onset not stated]. [Extracted from the article]

A 37-year-old woman with a history of congenital heart defects developed infective endocarditis and received antibiotic therapy with daptomycin. Despite undergoing various procedures and treatments, including pacemaker implantation and antibiotic therapy, she experienced severe complications and ultimately died due to refractory multiorgan failure. This case report highlights the lack of efficacy of daptomycin in this particular patient's condition. [Extracted from the article]

A descriptive study conducted between 2018 and 2022 examined three patients aged 2-15 years who experienced treatment failure while being treated with vancomycin for catheter-related bacteraemia (CRB). The patients had a history of haemophilia A or VII factor deficiency and developed CRB due to different bacteria. Despite receiving vancomycin, the treatment failed. The patients were then treated with amoxicillin/clavulanic acid or rifampicin, and in two of the patients, vancomycin treatment was continued before being switched to daptomycin, which resulted in negative blood cultures for all patients. [Extracted from the article]

A 59-year-old woman developed eosinophilic pneumonia while being treated with daptomycin for a methicillin-resistant staphylococcus aureus (MRSA) infection. The woman had a history of asthma and hypertension and had recently been diagnosed with shingles and treated with aciclovir and prednisone. After 15 days of daptomycin treatment, she developed fever, chills, and a productive cough. Chest imaging revealed pneumonia, and daptomycin was discontinued. The woman was then treated with vancomycin and showed improvement in her symptoms. A follow-up CT scan showed complete resolution of the pneumonia. [Extracted from the article]

A follow-up CT chest on hospital day 10 showed increased bilateral upper lobe consolidations and new consolidative opacities in the superior lower lobes. A CT chest, abdomen, and pelvis demonstrated the new multifocal upper lobe-predominant bilateral ground-glass opacities. A repeat CT chest performed approximately 1 week after discharge, which revealed the decreased upper lobe and superior lower lobe peri-bronchovascular consolidation with near resolution of surrounding ground glass opacities. [Extracted from the article]

One week later, she developed positive blood cultures for MSSA, persistent fever and showed local signs of infection (lack of efficacy). But on days 3, 6, and 9 after the treatment initiation, she had positive blood cultures for MSSA (lack of efficacy) and a repeated MRI revealed signs of pyomiositis of right gluteal muscle and L5-S1 discitis. On day 10, her treatment was switched to ceftaroline-fosamil and within 72 hours, her blood cultures were found to be negative for MSSA, and she remained with good clinical outcome. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In an observational study with data from open-access JADER database involving patients with muscle toxicity, diagnosed from April 2004 to July 2020, two patients [ I ages and sexes not stated i ] were described, who developed myopathy during treatment with daptomycin or vancomycin [ I indications not stated i ]. The patients with unspecified medical history, started receiving daptomycin or vancomycin therapy [ I dosages and routes not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 73-year-old man developed myoglobinuria and acute kidney injury (AKI) during the treatment with daptomycin for infected diabetic foot ulcer [ I dosage and route not stated; not all duration of treatment to reactions onset and outcomes stated i ]. A Unique Case of Daptomycin Induced Myoglobinuria and AKI With Normal Creatinine Phosphokinase Level. Initial, creatinine and creatinine phosphokinase level (CPK) was 0.88 mg/dL and 302 U/L, respectively. [Extracted from the article]

The patient, who had vancomycin-resistant I Enterococcus faecium i bloodstream infection, started receiving daptomycin and IV fosfomycin daily [ I not all routes stated; dosages not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a prospective observational multicentre study involving 106 patients enrolled from August 2016 to July 2020, et al. patient [ I age and sex not stated i ] was described, who developed elevated creatine kinase level following treatment with daptomycin and fosfomycin for vancomycin-resistant I Enterococcus faecium i bloodstream infection. Influence of daptomycin dose and fosfomycin susceptibility on outcome of vancomycin-resistant Enterococcus faecium bloodstream infections treated with daptomycin and fosfomycin combination. [Extracted from the article]

Bronchoalveolar lavage had 19% eosinophils and culture grew Klebsiella pneumonia, which was indicative concurrent bacterial pneumonia. Workup revealed leukocytosis with an absolute eosinophilic count of 2100/uL and an acute kidney injury (AKI) [ I aetiology not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 68-old-man developed eosinophilic pneumonia (EP) during antibiotic therapy with daptomycin [ I time to reaction onset not stated i ][1]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 86-year-old woman developed pancytopenia during treatment with levetiracetam, valproic acid or daptomycin for seizures or I Staphylococcus aureus i infection. She started receiving treatment with levetiracetam and valproic acid and cefepime was excluded. On fourth month of hospitalisation, she presented acute calculous cholecystitis and she received treatment with fasting, IV fluids and unspecified antibacterials [antibiotics] and gradual feeding per os. [Extracted from the article]

The woman's antibiotic regimen was changed to meropenem and daptomycin, and a CT scan was indicative of a perinephric abscess. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 36-year-old woman exhibited lack of efficacy during treatment with cefepime, meropenem and daptomycin for sepsis [ I dosages not stated; not all routes stated i ]. It was reported that, she was found to have sepsis secondary to a left perinephric abscess complicated by pulmonary septic emboli. [Extracted from the article]

Also, they developed haematological toxicity or skin toxicity during treatment with daptomycin, cloxacillin, levofloxacin, cotrimoxazole, linezolid or minocycline for MRSE infection [ I not all routes and dosages stated i ]. However, she developed skin toxicity by minocycline and haematological toxicity by linezolid [ I duration of treatment to reaction onset not stated i ]. [Extracted from the article]

The another patient started receiving treatment with IV daptomycin and developed a significant CK elevation indicating rhabdomyolysis. The 39-year-old patient with ESRD, started receiving treatment with IV daptomycin. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a single-centre, retrospective, descriptive study involving 50 patients with end-stage renal disease (ESRD), two patients (including a 39-year-old patient) [ I not all ages stated; sexes not stated i ] were described, who developed rhabdomyolysis during treatment with daptomycin [ I dosages, indications, durations of treatments to reactions onsets and outcomes not stated i ]. [Extracted from the article]